




Edition: BP 2025 (Ph. Eur. 11.6 update)

## Chlorprothixene Hydrochloride



### [General Notices](#)

(Ph. Eur. monograph 0815)



$C_{18}H_{19}Cl_2NS$  352.3 6469-93-8

### Action and use

Dopamine receptor antagonist; neuroleptic.

Ph Eur

## DEFINITION

(3Z)-3-(2-Chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine hydrochloride.

### Content

99.0 per cent to 101.0 per cent (dried substance).

## CHARACTERS

### Appearance

White or almost white, crystalline powder.

### Solubility

Soluble in water and in ethanol (96 per cent), slightly soluble in methylene chloride.

### mp

About 220 °C.

## IDENTIFICATION

First identification: A, E.

Second identification: B, C, D, E.

A. Infrared absorption spectrophotometry ([2.2.24](#)).

**Preparation** Dissolve 25 mg in 1 mL of [water R](#), add 0.1 mL of [dilute sodium hydroxide solution R](#) and shake with 2 mL of [methylene chloride R](#); separate the organic layer and wash with 0.5 mL of [water R](#); evaporate the organic layer to dryness and dry the residue at 40-50 °C; examine the residue as a disc.

**Comparison** Repeat the operations using 25 mg of [chlorprothixene hydrochloride CRS](#).

B. Dissolve 0.2 g in a mixture of 5 mL of [dioxan R](#) and 5 mL of a 1.5 g/L solution of [sodium nitrite R](#). Add 0.8 mL of [nitric acid R](#). After 10 min, add the solution to 20 mL of [water R](#). Filter the precipitate formed after 1 h. The filtrate is used immediately for identification test C. Dissolve the precipitate by warming in about 15 mL of [ethanol \(96 per cent\) R](#) and add the solution to 10 mL of [water R](#). Filter and dry the precipitate at 100-105 °C for 2 h. The melting point ([2.2.14](#)) is 152 °C to 154 °C.

C. To 1 mL of the filtrate obtained in identification test B, add 0.2 mL of a suspension of 50 mg of [fast red B salt R](#) in 1 mL of [ethanol \(96 per cent\) R](#). Add 1 mL of [0.5 M alcoholic potassium hydroxide](#). A dark red colour is produced. Carry out a blank test.

D. Dissolve about 20 mg in 2 mL of [nitric acid R](#). A red colour is produced. Add 5 mL of [water R](#) and examine in ultraviolet light at 365 nm. The solution shows green fluorescence.

E. Dissolve 20 mg in 2 mL of [water R](#), acidify with [dilute nitric acid R](#) and allow to stand for 5 min. Centrifuge. The supernatant gives reaction (a) of chlorides ([2.3.1](#)) starting from 'add 0.4 mL of [silver nitrate solution R1](#)'.

## TESTS

### Solution S

Dissolve 0.25 g in [carbon dioxide-free water R](#) and dilute to 25 mL with the same solvent.

### Appearance of solution

Solution S is clear ([2.2.1](#)) and colourless ([2.2.2, Method II](#)).

### pH ([2.2.3](#))

4.4 to 5.2 for solution S.

### Related substances

Liquid chromatography ([2.2.29](#)). Carry out the test protected from bright light.

**Test solution** Dissolve 20.0 mg of the substance to be examined in the mobile phase and dilute to 20.0 mL with the mobile phase.

**Reference solution (a)** Dilute 1.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

**Reference solution (b)** Dissolve the contents of a vial of [chlorprothixene for system suitability CRS](#) (containing impurities C and F) in 1 mL of the mobile phase.

**Column:**

— size:  $l = 0.10$  m,  $\varnothing = 4.0$  mm;

— stationary phase: [base-deactivated end-capped octadecylsilyl silica gel for chromatography R](#) (3  $\mu$ m).

**Mobile phase** Solution containing 6.0 g/L of [potassium dihydrogen phosphate R](#), 2.9 g/L of [sodium laurilsulfate R](#) and 9 g/L of [tetrabutylammonium bromide R](#) in a mixture of 50 volumes of [methanol R](#), 400 volumes of [acetonitrile R](#) and 550 volumes of [water for chromatography R](#).

**Flow rate** 1.0 mL/min.

*Detection* Spectrophotometer at 254 nm.

*Equilibration* For about 30 min with the mobile phase.

*Injection* 20 µL.

*Run time* Twice the retention time of chlorprothixene.

*Identification of impurities* Use the chromatogram supplied with [chlorprothixene for system suitability CRS](#) and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities C and F.

*Relative retention* With reference to chlorprothixene (retention time = about 10 min): impurity C = about 1.25; impurity F = about 1.33.

*System suitability* Reference solution (b):

— [resolution](#): minimum 3.0 between the peaks due to chlorprothixene and impurity C.

*Limits*:

— *impurity F*: not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent);

— *unspecified impurities*: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);

— *total*: not more than 8 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.8 per cent);

— *disregard limit*: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

#### [Loss on drying \(2.2.32\)](#)

Maximum 0.5 per cent, determined on 1.000 g by drying *in vacuo* at 60 °C for 3 h.

#### [Sulfated ash \(2.4.14\)](#)

Maximum 0.1 per cent, determined on 1.0 g.

## ASSAY

Dissolve 0.300 g in a mixture of 5.0 mL of [0.01 M hydrochloric acid](#) and 50 mL of [ethanol \(96 per cent\) R](#). Carry out a potentiometric titration ([2.2.20](#)), using [0.1 M sodium hydroxide](#). Read the volume added between the 2 points of inflexion.

1 mL of [0.1 M sodium hydroxide](#) is equivalent to 35.23 mg of C<sub>18</sub>H<sub>19</sub>Cl<sub>2</sub>NS.


## STORAGE

Protected from light.


## IMPURITIES

*Specified impurities* F.


*Other detectable impurities* (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph [Substances for pharmaceutical use \(2034\)](#). It is therefore not necessary to identify these impurities for demonstration of compliance. See also [5.10. Control of impurities in substances for pharmaceutical use](#)) A, B, C, D, E.




A. (3RS)-2-chloro-9-[3-(dimethylamino)propyl]-9H-thioxanthen-9-ol,




B. N,N-dimethyl-3-(9H-thioxanthen-9-ylidene)propan-1-amine,




C. (3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N-methylpropan-1-amine,



D. (3Z)-3-(4-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine,



E. 2-chloro-9H-thioxanthen-9-one,



F. (3E)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine ((E)-chlorprothixene).

